Human interleukin-4 receptor alpha antibodies
AssigneeEli Lilly and Company
InventorsShane Krummen Atwell, Yiqing Feng, Maya Rachel Karta, Donmienne Leung, Songqing Na, Diana Isabel Ruiz, David John Stokell, Laura Anne Pelletier
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to antibodies that specifically bind human IL-4Rα, compositions comprising such IL-4Rα antibodies, and methods of using such IL-4Rα antibodies.
Claims69
An antibody or antigen binding fragment thereof that specifically binds human IL-4Rα, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and the VL comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein:
- the HCDR1 comprises SEQ ID NO:
- 1;
- the HCDR2 comprises SEQ ID NO:
- 2;
- the HCDR3 comprises SEQ ID NO:
- 3;
- the LCDR1 comprises SEQ ID NO:
- 4;
- the LCDR2 comprises SEQ ID NO:
- 5;
- and
- the LCDR3 comprises SEQ ID NO:
- 6.
An antibody or antigen binding fragment thereof that specifically binds human IL-4Rα, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and the VL comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein:
- the HCDR1 comprises SEQ ID NO:
- 42;
- the HCDR2 comprises SEQ ID NO:
- 2;
- the HCDR3 comprises SEQ ID NO:
- 3;
- the LCDR1 comprises SEQ ID NO:
- 22;
- the LCDR2 comprises SEQ ID NO:
- 5;
- and
- the LCDR3 comprises SEQ ID NO:
- 6.
An antibody or antigen binding fragment thereof that specifically binds human IL-4Rα, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and the VL comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein:
- the HCDR1 comprises SEQ ID NO:
- 19;
- the HCDR2 comprises SEQ ID NO:
- 20;
- the HCDR3 comprises SEQ ID NO:
- 3;
- the LCDR1 comprises SEQ ID NO:
- 22;
- the LCDR2 comprises SEQ ID NO:
- 5;
- and
- the LCDR3 comprises SEQ ID NO:
- 24.
A nucleic acid comprising a sequence encoding SEQ ID NO:
- 9, 10, 13, 27, 28, 31, 33, 35, 37, 46, 47, 50, or 52.
A composition comprising a first vector comprising a nucleic acid sequence encoding SEQ ID NO:
- 9, 13, 31, 33, 35, 37, 46, 50, or 52 and a second vector comprising a nucleic acid sequence encoding SEQ ID NO:
- 10 or 47.
A composition comprising a first vector comprising a nucleic acid sequence encoding SEQ ID NO:
- 27, and a second vector comprising a nucleic acid sequence encoding SEQ ID NO:
- 28.
Dependencies are inferred from the claim text.